Persistent Atrial Fibrillation Study With The Breakthrough HeartLight® X3 System

LG Thin-Clients Feature Built-in RFID Capabilities Optimized for Use in Healthcare Facilities

Supporting its mission to help healthcare providers streamline operations and deliver exceptional patient care, LG Business Solutions USA introduced a new LG thin client...

Experien Group Acquired by Veranex

Veranex combines product development, regulatory, and market access expertise — globally and across complex and emerging markets.

CardioFocus, Inc. has announced the first enrollments in a clinical study evaluating use of the HeartLight X3 System in an early persistent AFib patient population. The 60 patient, prospective study will be led by Na Homolce Hospital (NHH) in Prague, Czech Republic. The company is dedicated to advancing ablation treatment for atrial fibrillation.

AFib, the most common type of cardiac rhythm disorder,1 is a progressive disease. If left untreated, patients suffering from paroxysmal AFib, with symptoms that come and go, will likely develop persistent AFib, a condition where the heart can no longer regulate its rhythm, with symptoms lasting longer than a week.

“We’ve used the HeartLight System since its inception, treating more than 500 patients and have seen first-hand the benefits it provides to AFib patients who suffer from this debilitating condition,” said Petr Neužil, MD, PhD, Head of the Department of Cardiology at NHH. “As the first center to use the HeartLight X3 System, we’ve been encouraged by the initial patient outcomes and are thrilled to initiate the evaluation of this next-generation device as a treatment for persistent AFib patients.”

For patients with paroxysmal AFib, pulmonary vein isolation (PVI) is a gold-standard catheter ablation treatment strategy and use of a PVI-only treatment approach for early persistent AFib has become progressively more common. The initial outcomes with the HeartLight System in the treatment of persistent AFib through a PVI-only approach have been encouraging:

  • A recent randomized multicenter study assessing the outcome of PVI in patients with persistent AFib concluded that PVI with the HeartLight System demonstrated similar efficacy to wide-area circumferential PVI using irrigated radio frequency ablation (RF).
  • As part of the study, researchers found that 71.2 percent of patients treated with the HeartLight System experienced freedom from AFib between 90 and 365 days after a single ablation, compared to 69.3 percent in the RF ablation group.2

PVI with the HeartLight X3 System utilizes laser energy to create lines of scar tissue to block the abnormal electrical pathways that cause AFib. Building upon the advanced features of the current HeartLight System – direct tissue visualization, titratable laser energy, and compliant balloon technology – the HeartLight X3 System is designed to deliver quick, continuous, circumferential lesions. The system’s unique RAPID mode leverages a precise motor control system that enables uninterrupted, high-speed lesion creation under direct control of the physician resulting in consistently reduced procedure times.

Throughout the recently completed paroxysmal AFib clinical evaluation, the HeartLight X3 System consistently achieved very rapid PVI, in as few as three minutes for a single pulmonary vein. Data from that study will be used to obtain regulatory approvals, with European CE Mark expected by mid-2019.

“We are grateful for our continued partnership with Dr. Neužil and his team at NHH, a leading cardiac center and global innovator,” said Burke T. Barrett, President and Chief Operating Officer at CardioFocus. “Our mutual commitment to continue the advancement of the HeartLight platform will bring breakthrough treatment options such as the X3 System to greater numbers of AFib patients around the world.”

The company reports: The HeartLight X3 System is an investigational device and not available for sale.


1 Chugh SS, Havmoeller R, Narayanan K, et al.; Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study. Circulation. 2014 Feb 25;129(8):837-47.
2 Circ Arrhythm Electrophysiol. 2017;10:e005767. DOI: 10.1161/CIRCEP.117.005767



Graham Belgrave Named to the 2021 PharmaVOICE 100 List of Distinguished Leaders

At Advanced Clinical, and from previous organizations, Belgrave serves as a mentor to several colleagues, where he challenges them to think outside of the box and take risks.

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.